Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Cathie Wood's ARK Investment bought 172.2K shares of Exact Sciences today  21:07
01/20/22
01/20
21:07
01/20/22
21:07
EXAS

Exact Sciences

$76.14 /

+0.05 (+0.07%)

 
ShowHide Related Items >><<
EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

EXAS Exact Sciences
$76.14 /

+0.05 (+0.07%)

Hot Stocks
U.S. appeals court asks Mylan to respond to Biogen request for patent rehearing » 14:43
01/20/22
01/20
14:43
01/20/22
14:43
BIIB

Biogen

$229.15 /

-1.88 (-0.81%)

, VTRS

Viatris

$14.79 /

+0.075 (+0.51%)

The United State Court of…

The United State Court of Appeals for the Federal Circuit has asked Viatris' (VTRS) Mylan to respond to Biogen's (BIIB) petition to have a case related to a Tecfidera patent reheard en banc, according to a letter posted by the court.

ShowHide Related Items >><<
VTRS Viatris
$14.79 /

+0.075 (+0.51%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

06:31 Today Barclays
Biogen price target lowered to $244 from $280 at Barclays
01/14/22 Jefferies
Biogen remains 'open to all options on the table,' says Jefferies
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/13/22 Guggenheim
Biogen downgraded to Neutral from Buy at Guggenheim
VTRS Viatris
$14.79 /

+0.075 (+0.51%)

12/09/21 Evercore ISI
Evercore 'conceptually' could understand a Viatris biosimilars deal with Biocon
06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
VTRS Viatris
$14.79 /

+0.075 (+0.51%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

VTRS Viatris
$14.79 /

+0.075 (+0.51%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

VTRS Viatris
$14.79 /

+0.075 (+0.51%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

VTRS Viatris
$14.79 /

+0.075 (+0.51%)

BIIB Biogen
$229.15 /

-1.88 (-0.81%)

Hot Stocks
Zymeworks falls -6.2% » 12:01
01/20/22
01/20
12:01
01/20/22
12:01
ZYME

Zymeworks

$12.61 /

-0.83 (-6.18%)

Zymeworks is down -6.2%,…

Zymeworks is down -6.2%, or -84c to $12.62.

ShowHide Related Items >><<
ZYME Zymeworks
$12.61 /

-0.83 (-6.18%)

ZYME Zymeworks
$12.61 /

-0.83 (-6.18%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$12.61 /

-0.83 (-6.18%)

ZYME Zymeworks
$12.61 /

-0.83 (-6.18%)

ZYME Zymeworks
$12.61 /

-0.83 (-6.18%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 09:34
01/20/22
01/20
09:34
01/20/22
09:34
AGEN

Agenus

$2.82 /

-0.035 (-1.23%)

, AZN

AstraZeneca

$59.46 /

-0.37 (-0.62%)

, BAYRY

Bayer

$14.82 /

+0.13 (+0.88%)

, BMY

Bristol-Myers

$64.73 /

-0.175 (-0.27%)

, CRDF

Cardiff Oncology

$4.54 /

-1.585 (-25.88%)

, DSNKY

Daiichi Sankyo

$22.44 /

-0.5385 (-2.34%)

, DCPH

Deciphera

$8.50 /

+0.225 (+2.72%)

, DNA

Ginkgo Bioworks

$5.04 /

-0.25 (-4.73%)

, ESALY

Eisai

$52.17 /

-0.39 (-0.74%)

, EXAS

Exact Sciences

$76.09 /

-1.24 (-1.60%)

, EXEL

Exelixis

$17.09 /

-0.28 (-1.61%)

, GH

Guardant Health

$71.99 /

-0.48 (-0.66%)

, HCM

Hutchmed

$29.71 /

-0.76 (-2.49%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.81 /

-0.19 (-0.25%)

, IPSEY

Ipsen

$24.15 /

+0.4145 (+1.75%)

, LLY

Eli Lilly

$245.08 /

-2.075 (-0.84%)

, MRK

Merck

$81.30 /

-0.25 (-0.31%)

, MRTX

Mirati Therapeutics

$120.93 /

+4.85 (+4.18%)

, NTRA

Natera

$61.27 /

+0.14 (+0.23%)

, NVCR

Novocure

$64.11 /

-0.37 (-0.57%)

, NVS

Novartis

$88.85 /

-0.7 (-0.78%)

, ORIC

Oric Pharmaceuticals

$11.72 /

-0.13 (-1.10%)

, PBLA

Panbela Therapeutics

$1.68 /

-0.06 (-3.45%)

, PFE

Pfizer

$53.54 /

-0.58 (-1.07%)

, SGEN

Seagen

$132.55 /

+2.2 (+1.69%)

, TPTX

Turning Point Therapeutics

$36.57 /

+0.44 (+1.22%)

, VCYT

Veracyte

$27.23 /

-0.54 (-1.94%)

, ZYME

Zymeworks

$13.44 /

+0.055 (+0.41%)

ASCO Gastrointestinal…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.44 /

-0.5385 (-2.34%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$52.17 /

-0.39 (-0.74%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$71.99 /

-0.48 (-0.66%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$29.71 /

-0.76 (-2.49%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.81 /

-0.19 (-0.25%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
01/04/22 Wells Fargo
Eli Lilly price target raised to $280 from $270 at Wells Fargo
MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$61.27 /

+0.14 (+0.23%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$64.11 /

-0.37 (-0.57%)

07:49 Today Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
06:15 Today Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$88.85 /

-0.7 (-0.78%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$132.55 /

+2.2 (+1.69%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
11/15/21 Roth Capital
Turning Point fundamentals strong heading into 2022, says Roth Capital
VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

TPTX Turning Point Therapeutics
$36.57 /

+0.44 (+1.22%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PBLA Panbela Therapeutics
$1.68 /

-0.06 (-3.45%)

ORIC Oric Pharmaceuticals
$11.72 /

-0.13 (-1.10%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NVCR Novocure
$64.11 /

-0.37 (-0.57%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

NTRA Natera
$61.27 /

+0.14 (+0.23%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

ZYME Zymeworks
$13.44 /

+0.055 (+0.41%)

VCYT Veracyte
$27.23 /

-0.54 (-1.94%)

SGEN Seagen
$132.55 /

+2.2 (+1.69%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRTX Mirati Therapeutics
$120.93 /

+4.85 (+4.18%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

IPSEY Ipsen
$24.15 /

+0.4145 (+1.75%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

GH Guardant Health
$71.99 /

-0.48 (-0.66%)

EXEL Exelixis
$17.09 /

-0.28 (-1.61%)

EXAS Exact Sciences
$76.09 /

-1.24 (-1.60%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

DCPH Deciphera
$8.50 /

+0.225 (+2.72%)

CRDF Cardiff Oncology
$4.54 /

-1.585 (-25.88%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

BAYRY Bayer
$14.82 /

+0.13 (+0.88%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

LLY Eli Lilly
$245.08 /

-2.075 (-0.84%)

INCY Incyte
$74.81 /

-0.19 (-0.25%)

DNA Ginkgo Bioworks
$5.04 /

-0.25 (-4.73%)

BMY Bristol-Myers
$64.73 /

-0.175 (-0.27%)

AZN AstraZeneca
$59.46 /

-0.37 (-0.62%)

AGEN Agenus
$2.82 /

-0.035 (-1.23%)

Hot Stocks
Japan's MHLW approves Pfizer, OPKO Health's NGENLA » 08:21
01/20/22
01/20
08:21
01/20/22
08:21
OPK

Opko Health

$4.43 /

-0.3 (-6.34%)

, PFE

Pfizer

$53.54 /

-0.58 (-1.07%)

Pfizer (PFE) Japan and…

Pfizer (PFE) Japan and OPKO Health (OPK) announced that the next generation long-acting growth hormone injection, NGENLA Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare, MHLW, in Japan. NGENLA is a once-weekly long-acting recombinant human growth hormone, for the indication of short statue due to growth hormone deficiency without closed epiphyses. This approval is based on the results of a Phase 3 study conducted in Japanese subjects and a global Phase 3 clinical study, both of which were conducted in subjects with pediatric GHD, and both of which compared the efficacy and safety of once-weekly NGENLA with GENOTROPIN. "We are pleased to receive approval for once-weekly NGENLA, which offers a new treatment option for pediatric GHD patients that can help reduce the burden associated with daily growth hormone administration. We wish to express our gratitude to the patients and their families who participated in the clinical studies and to all the sites conducting these trials," said Taro Ishibashi, President of Pfizer R&D Japan G.K.

ShowHide Related Items >><<
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

OPK Opko Health
$4.43 /

-0.3 (-6.34%)

OPK Opko Health
$4.43 /

-0.3 (-6.34%)

01/18/22 Piper Sandler
Opko Health price target raised to $6 from $5 at Piper Sandler
09/27/21 Barrington
Barrington says Somatrogon delay does not change Opko Health view
09/24/21 Piper Sandler
Piper confident in Opko's somatrogon approval despite BLA review delay
07/30/21 Barrington
Opko Health price target lowered to $6 from $8 at Barrington
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

OPK Opko Health
$4.43 /

-0.3 (-6.34%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

OPK Opko Health
$4.43 /

-0.3 (-6.34%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

Hot Stocks
Bausch Health: Dr. Yehia Hashad to join Bausch + Lomb as Chief Medical Officer » 07:11
01/20/22
01/20
07:11
01/20/22
07:11
BHC

Bausch Health

$25.57 /

-1.04 (-3.91%)

, ABBV

AbbVie

$135.21 /

-1.57 (-1.15%)

, NVS

Novartis

$88.85 /

-0.7 (-0.78%)

Bausch Health (BHC) has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

11/03/21 JPMorgan
Bausch Health earnings selloff a buying opportunity, says JPMorgan
09/21/21 JPMorgan
Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
08/04/21 JPMorgan
Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
08/04/21 Barclays
Bausch Health price target lowered to $31 from $35 at Barclays
ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

06:28 Today Barclays
AbbVie price target raised to $133 from $118 at Barclays
04:44 Today BMO Capital
Vertex upgraded to Outperform from Market Perform at BMO Capital
01/18/22 Cowen
AbbVie price target raised to $150 from $130 at Cowen
01/14/22 Piper Sandler
AbbVie approval comes with favorable label, says Piper Sandler
NVS Novartis
$88.85 /

-0.7 (-0.78%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

NVS Novartis
$88.85 /

-0.7 (-0.78%)

BHC Bausch Health
$25.57 /

-1.04 (-3.91%)

ABBV AbbVie
$135.21 /

-1.57 (-1.15%)

Hot Stocks
Merck's Keytruda combination featured in published Phase 3 study in carcinoma » 06:54
01/20/22
01/20
06:54
01/20/22
06:54
MRK

Merck

$81.30 /

-0.25 (-0.31%)

, ESALY

Eisai

$52.17 /

-0.39 (-0.74%)

Merck (MRK) and Eisai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$81.30 /

-0.25 (-0.31%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
ESALY Eisai
$52.17 /

-0.39 (-0.74%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

ESALY Eisai
$52.17 /

-0.39 (-0.74%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

Hot Stocks
IFF names Frank Clyburn as CEO, separates Chairman, CEO roles » 06:52
01/20/22
01/20
06:52
01/20/22
06:52
IFF

IFF

$139.35 /

-1.86 (-1.32%)

, MRK

Merck

$81.30 /

-0.25 (-0.31%)

IFF (IFF) announced the…

IFF (IFF) announced the appointment of Frank Clyburn to succeed Andreas Fibig as CEO and a member of the IFF Board of Directors, effective February 14. Clyburn joins IFF from Merck & Co. (MRK), where he currently serves as Executive Vice President and President of Human Health and has full P&L responsibility for nearly 90% of Merck's $48B business. He brings extensive experience leading complex global businesses and executing with exceptional operating discipline. Clyburn has an in-depth understanding of R&D, extensive integration and M&A experience and a unique ability to connect with customers and all stakeholders. He has built his career around impactful execution and while at Merck, built one of the leading oncology business in the world and the largest business within Merck. The company also announced its decision to separate the Chairman and CEO roles. Dale Morrison, long-standing IFF Director, will assume the role of non-executive Chairman of the Board of Directors, effective on February 14. Ed will remain on the Board as an Independent Director and the company will no longer have the Lead Independent Director role.

ShowHide Related Items >><<
MRK Merck
$81.30 /

-0.25 (-0.31%)

IFF IFF
$139.35 /

-1.86 (-1.32%)

IFF IFF
$139.35 /

-1.86 (-1.32%)

01/13/22 Jefferies
IFF initiated with a Buy at Jefferies
11/12/21 Deutsche Bank
IFF price target raised to $170 from $162 at Deutsche Bank
11/10/21 Wells Fargo
IFF price target raised to $170 from $160 at Wells Fargo
11/10/21 JPMorgan
IFF price target raised to $165 from $163 at JPMorgan
MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRK Merck
$81.30 /

-0.25 (-0.31%)

IFF IFF
$139.35 /

-1.86 (-1.32%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

IFF IFF
$139.35 /

-1.86 (-1.32%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

IFF IFF
$139.35 /

-1.86 (-1.32%)

Hot Stocks
Merck's EVP and President, Human Health, Frank Clyburn, to leave on Feb. 1 » 06:48
01/20/22
01/20
06:48
01/20/22
06:48
MRK

Merck

$81.30 /

-0.25 (-0.31%)

Merck announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

MRK Merck
$81.30 /

-0.25 (-0.31%)

Wednesday
Hot Stocks
Pfizer awarded $2.05B Army contract modification for more COVID-19 vaccine doses » 17:25
01/19/22
01/19
17:25
01/19/22
17:25
PFE

Pfizer

$53.54 /

-0.58 (-1.07%)

Pfizer was awarded a…

Pfizer was awarded a $2.05B modification to a contract for an additional 300M doses of COVID-19 vaccine for international donation to low and low-middle income countries. Work will be performed in New York, New York, with an estimated completion date of September 30. FY21 Coronavirus Response and Relief Supplemental Appropriations Act funds in the amount of $2.05B were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

ShowHide Related Items >><<
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

PFE Pfizer
$53.54 /

-0.58 (-1.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.